Benjamin M. Greenberg, MD, MHS / Jiwon Oh, MD, PhD, FRCPC - BTK Inhibition as an MS Treatment Modality: Where Do We Stand and Where Are We Headed?

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/YCW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An evolving understanding of the role of B cells in pathophysiology of multiple sclerosis (MS) and the demonstrated success of other B cell–targeted therapies have led to great interest in the promise of Bruton tyrosine kinase (BTK) inhibitors as a novel MS treatment class. Compared with anti-CD20 monoclonal antibodies, BTK inhibitors are understood to offer the promise of greater selectivity that leaves healthy B cells intact, as well as the ability to cross the blood–brain barrier and affect both the peripheral and central nervous systems. Four BTK inhibitors are now in phase 3 trials, with others in earlier stages of investigation. In this activity, based on a recent live symposium, expert speakers review the pathophysiologic rationale for BTK inhibition and discuss the emerging trial data on these agents. Upon completion of this activity, participants should be better able to: Explain the pathophysiologic rationale for Bruton tyrosine kinase (BTK) inhibition in multiple sclerosis (MS) management; Assess emerging evidence on the efficacy, safety, and tolerability of BTK inhibitors being studied for the treatment of MS; and Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities